Company Filing History:
Years Active: 2002
Title: The Innovative Contributions of Dan L Hensley
Introduction
Dan L Hensley is a notable inventor based in Huber Heights, OH (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of modified release formulations for medications. His work is especially relevant for the treatment of attention deficit hyperactivity disorder (ADHD) in children.
Latest Patents
Hensley's most recent patent is focused on Methylphenidate modified release formulations. This innovative pharmaceutical product is designed as a multiparticulate dosage form, specifically a once-a-day MR capsule. It is intended for children diagnosed with ADHD and is capable of delivering an initial rapid dose followed by a controlled release over approximately 12 hours. The formulation consists of multicoated particles made from two types of drug-layered beads: immediate release (IR) and extended release (ER) beads. The IR beads are created by layering an aqueous solution containing the drug and a binder onto non-pareil sugar spheres, followed by a seal coat. The ER beads are coated with a water-insoluble polymer, such as ethylcellulose, to control the dissolution rate. This innovative approach was developed through extensive clinical investigations and adheres to FDA guidelines.
Career Highlights
Throughout his career, Dan L Hensley has worked with reputable companies in the pharmaceutical industry, including Eurand America, Inc. and Shire Pharmaceuticals Ireland Limited. His experience in these organizations has contributed to his expertise in drug formulation and development.
Collaborations
Hensley has collaborated with several professionals in the field, including Marie J Bettman and Phillip J Percel. These collaborations have likely enhanced his research and development efforts, leading to successful innovations in pharmaceutical formulations.
Conclusion
Dan L Hensley's contributions to the field of pharmaceuticals, particularly through his patent on Methylphenidate modified release formulations, demonstrate his commitment to improving treatment options for children with ADHD. His innovative work continues to impact the pharmaceutical industry positively.